blinatumomab
astellas pharmaceuticals,amgen
['leusm', 'blinatumomab', 'leukemia']
congress #eha22 | anita rijneveld reports phase ii hovon trial results. the addition of blinatumomab in upfront therapy to prephase and after consolidation-1 increased mrd negativity and cr in 18-70 years old pts with nd cd19+ all. n=71 #allsm #leusm #leukemia 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm